LONDON--(BUSINESS WIRE)--Market research firm Technavio has announced the release of their latest report on the global alpha-1 antitrypsin drugs market. This new report will provide expert market insights for the forecast period 2018-2022.
The report will follow up on Technavio’s previous alpha-1 antitrypsin drugs report, offering an up-to-date analysis of the market, concerning the current market scenario, latest trends and drivers, and the overall global environment.
The upgraded research report on the alpha-1 antitrypsin drugs market is an integral part of Technavio’s cardiovascular and metabolic disorders portfolio. Technavio covers an extensive range of market research reports on the cardiovascular and metabolic disorders market, covering different regions and top industry segments. Some of the topics include peptide therapeutics, inflammatory bowel disease, liver cirrhosis therapeutics, and type 1 diabetes drugs.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Opportunities for growth
Technavio’s previous report on the global alpha-1 antitrypsin drugs market projected that the Americas showed the highest potential in 2015. This region is expected to be the largest market for alpha-1 antitrypsin drugs. During the forecast period, factors such as the recent rise in patient population and the rising uptake of biologic drugs will propel market growth.
In the previous report, a senior research analyst at Technavio stated, “The primary growth driver for this market is the improved diagnosis of alpha-1 antitrypsin deficiency. According to the Alpha-1 Foundation, nearly 3% of all people diagnosed with COPD may have undetected AAT deficiency. Companies in this market aid in the rapid identification of the mutated Z gene.”
Technavio’s new report on the global alpha-1 antitrypsin drugs market will evaluate the key geographical regions and their behavior over the past four years, introducing new data and observations and providing new predictions.
Looking for the latest information on the global alpha-1 antitrypsin drugs market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Detailed analysis at your fingertips
Some of the topics that will be revisited in the new report include:
- Market size and growth rate through 2022
- Top factors driving the market growth
- Competitive landscape of the market
- Market opportunities and factors impeding growth
The report on the global alpha-1 antitrypsin drugs market for the period 2018-2022 is available to order now and will be delivered within one week of purchase.
Technavio’s best deals of the month!
Technavio supports Health for All campaign on this World Health Day with 20% savings on all reports in the Health and Wellness category for the entire month.
Celebrate International Astronomy Day by indulging in a whopping 30% savings on all reports in the Space category. Offer valid from 16th April for a limited period.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.